

# Clinical Evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV *PLUS* Combination Test

Grant Johnson<sup>1,2</sup>, Branden S.J. Gregorchuk<sup>3</sup>, Arek Zubrzycki<sup>1</sup>, Kurt Kolsun<sup>3,4</sup>, Adrienne F.A. Meyers<sup>3,5</sup>, Paul A. Sandstrom<sup>3,5</sup>, Michael G. Becker<sup>3,4,\*</sup>

<sup>1</sup> Laboratory Medicine and Infection Prevention and Control, Lakeridge Health, Oshawa, Ontario, Canada.

<sup>2</sup> Ontario Tech University, Oshawa, Ontario, Canada.

<sup>3</sup> National HIV and Retrovirology Laboratories, National Microbiology Laboratory Branch, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada

<sup>4</sup> Department of Microbiology, University of Manitoba, Winnipeg, Canada

<sup>5</sup> Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada

\* Correspondence: [michael.glen.becker@phac-aspc.gc.ca](mailto:michael.glen.becker@phac-aspc.gc.ca)

## Abstract

The GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV *PLUS* combination test (*PLUS* Assay) received Health Canada approval in January 2022. The *PLUS* Assay is similar to the SARS-CoV-2/Flu/RSV combination test, with modifications to improve assay robustness against circulating and emerging variants. The performance characteristics of the *PLUS* Assay were assessed at the Lakeridge Health Oshawa Hospital Centre and the National Microbiology Laboratory of Canada. The *PLUS* Assay was directly compared to the SARS-CoV-2/Flu/RSV combination test using SARS-CoV-2 culture from five variants and remnant clinical specimens collected across the COVID-19 pandemic. This included 50 clinical specimens negative for all pathogens, 110 clinical specimens positive for SARS-CoV-2, Influenza A, Influenza B, RSVA, and/or RSVB and an additional 11 mixed samples to screen for target interactions. The *PLUS* Assay showed a high percent agreement with the widely used SARS-CoV-2/Flu/RSV combination test. Based on these findings, the *PLUS* Assay and the Xpert SARS-CoV-2/Flu/RSV combination test results are largely consistent with no observed difference in sensitivity, specificity, or time to result when challenged with various SARS-CoV-2 variants. The reported Ct values provided by the new *PLUS* Assay was also unchanged, with the exception of a possible 1-2 decrease reported Ct for RSVA across a limited sample size.

## 31 Introduction

32 The coronavirus disease 2019 (COVID-19) pandemic has lead to an enormous demand  
33 for diagnostic testing. To this end, numerous antigen and molecular SARS-CoV-2 rapid tests  
34 have been approved by the United States Food and Drug Administration and Health Canada,  
35 including the Cepheid GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV Combination Test.  
36 The GeneXpert and its associated COVID-19 cartridges perform a rapid, fully-automated, and  
37 self-contained multiplex RT-qPCR tests with run times of 45 minutes or less (Cepheid Package  
38 Insert, 2021). The Xpert SARS-CoV-2/Flu/RSV assay targets two SARS-CoV-2 genomic regions,  
39 the envelope (E) and the nucleocapsid (N2) returning a cycle threshold (Ct) value if the target is  
40 detected as well as its qualitative result interpretation within 45 amplification cycles. The results  
41 for the SARS-CoV-2/Flu/RSV combination test reports the fluorescence values for both the E and  
42 N2 targets of SARS-CoV-2 as a single result as they occupy the same fluorescence channel  
43 (Johnson *et al.*, 2021). Additionally, the Xpert SARS-CoV-2/Flu/RSV combination test is able to  
44 detect influenza A, influenza B as well as respiratory syncytial virus (RSV), and will report their  
45 respective Ct values.

46 As SARS-CoV-2 variants of concern continue to emerge worldwide, Cepheid developed  
47 a new formulation of their Xpert SARS-CoV-2/Flu/RSV combination test, the Xpert SARS-CoV-  
48 2/Flu/RSV *PLUS* combination test (referred to hereafter as the *PLUS* Combination Test). The  
49 *PLUS* Combination Test has an additional SARS-CoV-2 target, RNA-Dependent RNA  
50 Polymerase (RdRp), to help improve assay robustness against novel SARS-CoV-2 variants and  
51 redesigned N2 oligos for better coverage of nucleocapsid mutations in circulation that have  
52 been shown to cause N gene detection dropout using GeneXpert SARS-CoV-2 assays (Foster *et*  
53 *al.*, 2022; Isabel *et al.*, 2022). RdRp (also known as nsp-12) is the catalytic subunit of multi-  
54 subunit polymerase complex which, along with nsp-7 and nsp-8, forms the minimal core  
55 components for SARS-CoV-2 RNA synthesis (Peng *et al.*, 2020). To date, there has been no  
56 identified RdRp modifications, with this region being considered relatively stable target due to  
57 its conserved function (te Velthuis *et al.*, 2009; Pachetti *et al.*, 2020; Peng *et al.*, 2020). RdRp is

58 measured on the same fluorescence channel as targets E and N2, and thus a single Ct value is  
59 reported for SARS-CoV-2.

60 As a rapid near-point-of-care device, the GeneXpert system is currently used as a testing  
61 option to improve turnaround times in major health centres, and is used heavily in critical care  
62 settings (Jokela *et al.*, 2020; Gotham *et al.*, 2021). Additionally, the GeneXpert has been a reliable  
63 tool for decentralized testing in remote and isolated Canadian communities (Respiratory Virus  
64 Infections Working Group, 2020) where access to large, well-equipped laboratories is not  
65 possible (Berry *et al.*, 2020; Jokela *et al.*, 2020; Gotham *et al.*, 2021; Yau *et al.*, 2021; Rong *et al.*,  
66 2022). It has also been used internationally by the World Health Organization in developing  
67 countries during their response to the COVID-19 pandemic (Rakotosamimanana *et al.*, 2020;  
68 World Health Organization, 2020).

69 The individual Xpert Xpress SARS-CoV-2 and Xpert Xpress Flu/RSV assays have  
70 demonstrated high sensitivity in numerous analytical and clinical studies with company  
71 reported sensitivity of 100% (n=35) at 250 copies (cp)/mL for its SARS-CoV-2 assay; independent  
72 studies have reported a limit of detection (LOD) ranging from 8.3 – 60 cp/mL (3–4). Indeed, the  
73 assay has shown excellent agreement with the Roche Cobas 6800 system (Broder *et al.*, 2020;  
74 Goldenberger *et al.*, 2020; Lieberman *et al.*, 2020; Moran *et al.*, 2020; Smithgall *et al.*, 2020; Tham *et*  
75 *al.*, 2021), the Hologic Panther Fusion (Hogan *et al.*, 2020), as well as laboratory-developed RT-  
76 qPCR tests (Lieberman *et al.*, 2020; Wolters *et al.*, 2020). A recent systematic review of the Xpert  
77 Xpress assay indicated an overall specificity and sensitivity of 97% based on a selection of 11  
78 studies (Goldenberger *et al.*, 2020). As the GeneXpert is present a plethora of settings (including  
79 clinics, hospitals, health centres, nursing stations), an independent evaluation of the recently  
80 approved *PLUS* Combination Test ahead of the approaching flu season is essential.

81 In our study, remnant clinical samples of SARS-CoV-2, influenza A (H3 and H1 2009),  
82 influenza B, RSVA, and RSVB were used to evaluate the *PLUS* Combination Test and compare  
83 it to the SARS-CoV-2/Flu/RSV Combination Test (Johnson *et al.*, 2022). This evaluation was  
84 performed in two independent laboratories, the National Microbiology Laboratory (NML;  
85 Winnipeg, Canada) and Lakeridge Health Oshawa Hospital (Oshawa, Canada). The SARS-CoV-

86 2 samples used in this study were collected across multiple waves of the pandemic, and  
87 included SARS-CoV-2 Alpha, Delta, Omicron BA.1, and Omicron BA.2 variants. Additionally,  
88 inactivated SARS-CoV-2 culture from five variants was tested on both assays. No difference was  
89 observed between the assays concerning sensitivity, reported Ct value, run time, or specificity.

## 90 **Materials and Methods**

### 91 Clinical Specimens

92 Remnant universal transport media (UTM) from nasopharyngeal or nasal clinical swabs  
93 collected at the Cadham Provincial Laboratory (Winnipeg, Canada), Lakeridge Health Oshawa  
94 Hospital (Oshawa, Canada), and the Public Health Ontario Laboratory (Toronto, Canada) were  
95 used. Study samples included 50 clinical specimens negative for SARS-CoV-2, Influenza A,  
96 Influenza B, and RSV, with an additional 99 clinical positive specimens containing any one or  
97 more of the following pathogens: SARS-CoV-2, Influenza A, Influenza B, or RSV. Fifty-nine of  
98 the study samples (50 negatives, 7 COVID-19 positive, 2 Influenza positive) were obtained from  
99 prospective sampling of patients presenting with COVID-19 symptoms. The remainder of the  
100 study samples were previously characterized by laboratory-developed RT-qPCR tests (i.e. the  
101 ResPlex Assay or the Cepheid GeneXpert with the SARS-CoV-2/Flu/RSV Combination Test;  
102 Supplemental Data 1). Selected samples were stratified to cover a wide range of Ct values, from  
103 approximately 15-40. All samples tested at the National Microbiology Laboratory of Canada  
104 each RSV sample were typed as RSVA or RSVB, which is indicated in Supplemental Data 1. In  
105 total, this study included 7 RSVA samples, 9 RSVB samples, and 10 RSV samples that were not  
106 typed.

107 To simulate patient coinfection with multiple viruses, remnant transport media from an  
108 additional 26 clinical specimens were mixed in various combinations to create 11 contrived  
109 samples, each containing two or three different respiratory viral pathogens, and tested using  
110 both Xpert assays (Supplemental Data 1). All samples used in this study were research ethics  
111 board-exempt, anonymized, diagnostic samples used for assay validation. To determine overall

112 test agreement, 300  $\mu$ L of transport media from nasal or nasopharyngeal swabs was tested in  
113 parallel with the SARS-CoV-2/Flu/RSV combination test and the *PLUS* Combination Test. .

114

#### 115 Gamma-irradiated SARS-CoV-2 culture

116 High-titre inactivated SARS-CoV-2 culture of the Alpha (B.1.1.7), Delta (B.1.617.2),  
117 Omicron BA.1 (BA.1), Omicron BA.2 (BA.2), and wild type (WA-1) variants was provided by  
118 the Special Pathogens Program of the National Microbiology Laboratory Branch (NMLB;  
119 Winnipeg, MB). SARS-CoV-2 variants were propagated in Vero cells in Minimal Essential  
120 Medium and clarified by low speed centrifugation. The viral supernatant was inactivated via  
121 gamma-irradiation using a Gammacell 220 Cobalt-60 irradiator with a total exposure of three  
122 Mrad of radiation. The reported stock concentrations of the viral variant preparations were  
123  $2.1 \times 10^6$  PFU/mL (Alpha),  $2.3 \times 10^5$  PFU/mL (Delta),  $2.1 \times 10^5$  PFU/mL (Omicron BA1),  $1.9 \times 10^5$   
124 PFU/mL (Omicron BA.2), and  $1.2 \times 10^6$  PFU/mL (wild type). Inactivated culture fluid was serially  
125 diluted in UTM and Ct values were determined using the GeneXpert® Xpert® Xpress SARS-  
126 CoV-2 assay. Dilutions were performed to obtain Ct values of approximately 33 and 36,  
127 approaching the limit of detection of the GeneXpert assay. Ct values were converted into cp/mL  
128 using a standard curve (Becker *et al.*, 2020). Characterization of dilutions are summarized in  
129 Table 1. 300  $\mu$ L of the diluted culture fluid was tested in duplicate using both the SARS-CoV-  
130 2/Flu/RSV combination test and the *PLUS* Combination Test.

131

#### 132 **Results**

133 Inactivated gamma-irradiated SARS-CoV-2 culture of five isolates (Wild-Type (WA-1),  
134 Alpha (B.1.1.7), Delta (B.1.617.2), Omicron (BA.1), and Omicron (BA.2)) were used to investigate  
135 the performance of the *PLUS* Combination Test against current or previous circulating variants.  
136 A panel of five cultured SARS-CoV-2 isolates was tested with the SARS-CoV-2/Flu/RSV  
137 combination test and the *PLUS* Combination Test (Table 1). All variants were detected with  
138 both assays at all dilutions and replicates. Additionally, SARS-CoV-2 positive and SARS-CoV-2  
139 negative clinical samples were tested with both the *PLUS* Combination Test and SARS-CoV-

140 2/Flu/RSV combination test (Table 2). The Ct values of SARS-CoV-2 positive samples ranged  
141 from 15.6 to 43.5 (Fig. 1; Supplemental Data 1). There was 100% agreement between both assays,  
142 with 57 positives and 103 negatives detected (Table 2). There was a high level of correlation  
143 between the SARS-CoV-2 Ct values reported with both of the assays (Figure 1;  $R^2 = 0.973$ ), with  
144 an average standard deviation of 0.49 Ct values between the reported results (Supplemental  
145 Data 1).

146 The above process was repeated for clinical samples containing Influenza A, Influenza B,  
147 and RSV. Similarly, results were highly consistent between the *PLUS* Combination Test and  
148 SARS-CoV-2/Influenza/RSV combination test, with overall percent agreements of 100%, 99.4%,  
149 and 100% for influenza A, influenza B, and RSV, respectively (Table 3). Regardless of RSV  
150 subtype, all RSV positive clinical samples were detected using both assays (Table 3;  
151 Supplemental Data 1). Likewise, high correlations were observed between the Ct values  
152 reported by both Xpert assays for influenza A (Figure 1;  $R^2 = 0.978$ ), influenza B ( $R^2 = 0.984$ ), and  
153 RSV ( $R^2 = 0.975$ ). The correlation for RSV targets was maintained when broken down further by  
154 subtype (Supplemental Figure 1). Variance between the Ct values reported by each assay was  
155 also low for all targets, with an average Ct value standard deviation of 0.22 for influenza A, 0.24  
156 for influenza B, and 0.36 for RSV (Supplemental Data 1). When RSV was analyzed by subtype,  
157 average Ct value standard deviation was greatest for RSVA at 0.72 ( $n=7$ ), with measured Ct  
158 values an average of 1.4 cycles lower with the *PLUS* Combination Test (Supplemental Figure 1;  
159 Supplemental Data 1). The average run time from insertion of the cartridge to its ejection was  
160 timed for both the *PLUS* Combination Test and SARS-CoV-2/Flu/RSV Combination Test. There  
161 was no difference in run time between the two assays, with an average of 36.5 minutes to assay  
162 completion (Supplemental Data 1).

## 163 Discussion and Conclusion

164 In an effort to improve assay performance against emerging SARS-CoV-2 variants the  
165 *PLUS* Combination Test introduces an additional SARS-CoV-2 target (RdRp), as this region has  
166 is unmodified in all circulating variants of concern (te Velthuis *et al.*, 2009; Pachetti *et al.*, 2020;  
167 Peng *et al.*, 2020), and has introduced redesigned N2 oligos for better coverage of circulating

168 mutations that caused N gene target dropout (Foster *et al.*, 2022; Isabel *et al.*, 2022). Here, we  
169 investigated the performance characteristics of the *PLUS* Combination Test comparing it to the  
170 SARS-CoV-2/Flu/RSV combination test authorized for use in Canada since January, 2021. This  
171 study used a total of 160 clinical samples (including mixtures) that were processed at two  
172 independent institutions, of which 110 samples were positive for SARS-CoV-2, influenza A,  
173 influenza B, RSVA, and/or RSVB. There was no observable difference in assay run time,  
174 sensitivity, specificity, or reported Ct value between the *PLUS* Combination Test and SARS-  
175 CoV-2/Flu/RSV combination test – with the possible exception of a slight decrease in RSVA Ct  
176 value with the *PLUS* Combination Test across a small number of samples. Overall, the results  
177 between the two assays were nearly identical for all targets, with agreement approaching 100%.  
178 The only discordant sample between the two assays was a high-Ct (32.3) Influenza B sample  
179 detected only with the SARS-CoV-2/Flu/RSV Combination Test. This likely reflects detection  
180 variability due to the low concentration of the target near its LOD, rather than a difference in  
181 performance between the two assays.

182 This observation was consistent for all variants tested. These results demonstrate that  
183 the Ct value for RdRp detection of SARS CoV-2 likely falls at or above the E and N2 targets  
184 producing little to no change to the reported Ct value. In conclusion, as the performance  
185 characteristics of the tests are nearly identical, the *PLUS* Combination Test can effectively  
186 replace the SARS-CoV-2/Flu/RSV combination test.

## 187 **References**

- 188 Becker, M. G. *et al.* (2020) 'Recommendations for sample pooling on the Cepheid GeneXpert® system using the  
189 Cepheid Xpert® Xpress SARS-CoV-2 assay', *PLOS ONE*. Edited by J.-L. E. Darlix. Public Library of Science, 15(11), p.  
190 e0241959. doi: 10.1371/journal.pone.0241959.
- 191 Berry, L. *et al.* (2020) 'Point of care testing of Influenza A/B and RSV in an adult respiratory assessment unit is  
192 associated with improvement in isolation practices and reduction in hospital length of stay', *Journal of Medical*  
193 *Microbiology*, 69(5), pp. 697–704. doi: 10.1099/jmm.0.001187.
- 194 Broder, K. *et al.* (2020) 'Test agreement between roche cobas 6800 and cepheid genexpert xpress sars-cov-2 assays  
195 at high cycle threshold ranges', *Journal of Clinical Microbiology*, 58(8). doi: 10.1128/JCM.01187-20.
- 196 Cepheid Package Insert (2021) 'Xpert® Xpress SARS-CoV-2/Flu/RSV Instructions For Use with GeneXpert Dx or  
197 GeneXpert Infinity Systems'. Cepheid, 302–5707(Rev. A).
- 198 Foster, C. S. *et al.* (2022) 'SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay  
199 instability', *Pathology*, 54(4): 499–501.
- 200 Goldenberger, D. *et al.* (2020) 'Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay', *Journal of*

- 201 *Virological Methods*, 284(July), pp. 8–10. doi: 10.1016/j.jviromet.2020.113925.
- 202 Gotham, D. *et al.* (2021) 'Public investments in the development of GeneXpert molecular diagnostic technology',  
203 *PLoS ONE*, 16(8 August). doi: 10.1371/journal.pone.0256883.
- 204 Hogan, C. A. *et al.* (2020) 'Five-minute point-of-care testing for SARS-CoV-2: Not there yet', *Journal of Clinical*  
205 *Virology*. Elsevier B.V., 128. doi: 10.1016/J.JCV.2020.104410.
- 206 Isabel, S. *et al.* (2022) 'Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR  
207 detection in Canada', *Scientific Reports*, 12(1), 1-7.
- 208 Johnson, G. *et al.* (2021) 'Clinical evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV combination  
209 test', *Journal of Clinical Virology Plus*, 1(1), pp. 100014. doi: 10.1016/j.jcvp.2021.100014.
- 210 Johnson, G. *et al.* (2022) 'Clinical Evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV PLUS  
211 Combination Test', *medRxiv*. Cold Spring Harbour Laboratory Press, p. 2022.11.07.22281957. doi:  
212 <https://doi.org/10.1101/2022.11.07.22281957>
- 213 Jokela, P. *et al.* (2020) 'SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department:  
214 evaluation and utility', *Journal of Clinical Virology*. Elsevier B.V., 131. doi: 10.1016/J.JCV.2020.104614.
- 215 Lieberman, J. *et al.* (2020) 'Comparison of Commercially Available and Laboratory Developed Assays for in vitro  
216 Detection of SARS-CoV-2 in Clinical Laboratories', *medRxiv*. Cold Spring Harbor Laboratory Press, p.  
217 2020.04.24.20074559. doi: 10.1101/2020.04.24.20074559.
- 218 Moran, A. *et al.* (2020) 'The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas  
219 SARS-CoV-2 Assays', *Journal of Clinical Microbiology*. American Society for Microbiology Journals. doi:  
220 10.1128/JCM.00772-20.
- 221 Pachetti, M. *et al.* (2020) 'Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA  
222 polymerase variant', *J Transl Med*, 18, p. 179. doi: 10.1186/s12967-020-02344-6.
- 223 Peng, Q. *et al.* (2020) 'Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase  
224 Complex from SARS-CoV-2', *Cell Reports*, 31(11). doi: 10.1016/j.celrep.2020.107774.
- 225 Rakotosamimanana, N. *et al.* (2020) 'GeneXpert for the diagnosis of COVID-19 in LMICs', *The Lancet Global Health*.  
226 Elsevier Ltd, 8(12), pp. e1457–e1458. doi: 10.1016/S2214-109X(20)30428-9.
- 227 Respiratory Virus Infections Working Group (2020) 'Canadian Public Health Laboratory Network: Prioritized  
228 support for northern, remote and isolated communities in Canada', *Can Commun Dis Rep*, 46(10), pp. 322–323.  
229 doi: 10.14745/ccdr.v46i10a02.
- 230 Rong, K. *et al.* (2022) 'Validation of the Cepheid Xpert® Xpress SARS-CoV-2 using upper and lower respiratory tract  
231 specimens', *European Journal of Microbiology and Immunology*. Akadémiai Kiadó, 12(1), pp. 18–21. doi:  
232 10.1556/1886.2022.00003.
- 233 Smithgall, M. C. *et al.* (2020) 'Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid  
234 Detection of SARS-CoV-2', *bioRxiv*. Cold Spring Harbor Laboratory, p. 2020.04.22.055327. doi:  
235 10.1101/2020.04.22.055327.
- 236 Tham, J. W. M. *et al.* (2021) 'Parallel testing of 241 clinical nasopharyngeal swabs for the detection of SARS-CoV-2  
237 virus on the Cepheid Xpert Xpress SARS-CoV-2 and the Roche cobas SARS-CoV-2 assays', *Clinical Chemistry and*  
238 *Laboratory Medicine*. De Gruyter Open Ltd, 59(2), pp. E45–E48. doi: 10.1515/CCLM-2020-  
239 1338/MACHINEREADABLECITATION/RIS.
- 240 te Velhuis, A. J. W. *et al.* (2009) 'The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent',  
241 *Nucleic Acids Research*, 38(1), pp. 203–214. doi: 10.1093/nar/gkp904.
- 242 Wolters, F. *et al.* (2020) 'Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the  
243 SARS-CoV-2 pandemic', *Journal of Clinical Virology*. Elsevier, 128(May 2020), p. 104426. doi:  
244 10.1016/j.jcv.2020.104426.



245 World Health Organization (2020) 'Rapid communication on the role of the GeneXpert<sup>®</sup> platform for rapid  
246 molecular testing for SARS-CoV-2 in the WHO European Region European Laboratory Initiative on TB, HIV and Viral  
247 Hepatitis: 1 April 2020', (April). Available at: <https://apps.who.int/iris/handle/10665/336322> (Accessed: 9  
248 September 2022).

249 Yau, F. *et al.* (2021) 'Clinical utility of a rapid "on-demand" laboratory-based SARS-CoV-2 diagnostic testing service  
250 in an acute hospital setting admitting COVID-19 patients', *Clinical Infection in Practice*. Elsevier B.V., 12. doi:  
251 10.1016/J.CLINPR.2021.100086.

252 Zhen, W. *et al.* (2020) 'Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2',  
253 *Journal of Clinical Microbiology*. American Society for Microbiology Journals. doi: 10.1128/JCM.00783-20.

254

255

256 The authors have no competing interests to disclose.

257 All primary research data used to generate this manuscript are included in-text and within Supplementary file 1.

**Table 1:** Detection of five SARS-CoV-2 Variants. Materials tested were cultured SARS-CoV-2, inactivated by gamma-irradiation. SARS-CoV-2 concentrations were adjusted to target Ct values of 33 and 36, followed by testing with the Xpert SARS-CoV-2/Flu/RSV Combination Test or Xpert SARS-CoV-2/Flu/RSV PLUS Combination Test. Each dilution was tested in duplicate (indicated as Replicate 1 [Rep1] and Replicate 2 [Rep2] below).

	SARS-CoV-2 Variant (inactivated culture)	SARS-CoV-2 /Flu/RSV		SARS-CoV-2 /Flu/RSV PLUS	
		Rep1	Rep2	Rep1	Rep2
Ct = 33	Wild Type WA-1	30.2	32.2	32.9	32.8
	Alpha B.1.1.7	32.2	32.1	33.4	33.2
	Delta B.1.617.2	33.7	33.8	34.2	34.8
	Omicron BA.1.1	33.7	32.3	33.2	32.7
	Omicron BA.2	33.7	33.4	33.0	32.4
Ct = 36	Wild Type WA-1	35.8	35.5	36.1	36.0
	Alpha B.1.1.7	35.4	35.7	35.6	36.1
	Delta B.1.617.2	36.4	36.4	37.3	37.5
	Omicron BA.1.1	36.4	37.1	35.8	35.9
	Omicron BA.2	36.2	37.6	36.0	35.3


Note: Ct: Cycle threshold

**Table 2:** Concordance of the Xpert SARS-CoV-2/Flu/RSV Combination Test with the Xpert SARS-CoV-2/Flu/RSV PLUS Combination Test for the detection of SARS-CoV-2.

Result with Xpert SARS- CoV-2/Flu/RSV	Result with Xpert SARS-CoV- 2/Flu/RSV PLUS	
	SARS-CoV-2 Positive	Negative
Positive	57	0
Negative	0	103

**Table 3:** Concordance of the Xpert SARS-CoV-2/Flu/RSV Combination Test with the SARS-CoV-2/Flu/RSV *PLUS* Combination Test for the detection of Influenza A, Influenza B and RSV.

Result with Xpert SARS- CoV-2/Flu/RSV	Result with Xpert SARS-CoV-2/Flu/RSV <i>PLUS</i>					
	Influenza A		Influenza B		RSVA/B	
	Positive	Negative	Positive	Negative	Positive	Negative
Positive	21	0	19	1	25	0
Negative	0	139	0	140	0	135



**Figure 1:** Ct value comparisons between the Xpert SARS-CoV-2/Flu/RSV Combination Test and SARS-CoV-2/Flu/RSV PLUS Combination Test. Results shown for: A) SARS-CoV-2; B) Respiratory Syncytial Virus; C) Influenza A; and D) Influenza B. Correlation (R<sup>2</sup>) is calculated for each target.